Mitotic Stability of Small Supernumerary Marker Chromosomes: A Study Based on 93 Immortalized Cell Lines


Creative Commons License

Spittel H., Kubek F., Kreskowski K., Ziegler M., Klein E., Hamid A. B., ...More

CYTOGENETIC AND GENOME RESEARCH, vol.142, no.3, pp.151-160, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 142 Issue: 3
  • Publication Date: 2014
  • Doi Number: 10.1159/000360776
  • Journal Name: CYTOGENETIC AND GENOME RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.151-160
  • Keywords: Cell bank, Cell lines, Epstein-Barr virus immortalization, Marker chromosome shape, Puberty, Small supernumerary marker chromosome
  • Gazi University Affiliated: Yes

Abstract

Small supernumerary marker chromosomes (sSMC) are known for being present in mosaic form as 47,+mar/46 in >50% of the cases with this kind of extra chromosomes. However, no detailed studies have been done for the mitotic stability of sSMC so far, mainly due to the lack of a corresponding in vitro model system. Recently, we established an sSMC-cell bank (Else Kroner-Fresenius-sSMC-cellbank) with >150 cell lines. Therefore, 93 selected sSMC cases were studied here for the presence of the corresponding marker chromosomes before and after Epstein-Barr virus-induced immortalization. The obtained results showed that dicentric inverted duplicated-shaped sSMC are by far more stable in vitro than monocentric centric minute-or ring-shaped sSMC. Simultaneously, a review of the literature revealed that a comparable shape-dependent mitotic stability can be found in vivo in sSMC carriers. Additionally, a possible impact of the age of the sSMC carrier on mitotic stability was found: sSMC cell lines established from patients between 10-20 years of age were predominantly mitotically unstable. The latter finding was independent of the sSMC shape. The present study shows that in vitro models can lead to new and exciting insights into the biology of this genetically and clinically heterogeneous patient group. (C) 2014 S. Karger AG, Basel